Felis ISSN 2398-2950


Contributor(s): Dwight Bowman, Linda Horspool, Ian Wright



  • Fluralaner, Bravecto®.

Class of drug

  • Ectoparasiticides for systemic use.
  • Isoxazoline.
  • Systemic insecticide and acaricide.


Chemical name

  • 4-[(5R)-5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide.

Molecular formula

  • C22H17Cl2F6N3O3

Molecular weight

  • 556.28

Physical properties

  • Spot-on solution.
  • Clear, colorless to yellow solution.

Storage requirements

  • Shelf life as packaged for sale: 2 years.
  • Do not store above 86°F (30°C).
  • Pipettes should be kept in the outer packaging to prevent solvent loss or moisture uptake. The sachets should only be opened immediately prior to use.


This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login


  • Treatment and prevention of flea infestations for 12 weeks.
  • Immediate and persistent flea killing activity for 12 weeks:
    • Onset of effect 100% of fleas (C. felis) killed within 8 hours after treatment and >98% within 12 hours.
    • Newly emerged fleas are killed before viable eggs are produced.
    • In vitro very low concentrations of fluralaner stop the production of viable eggs by fleas.
    • Flea life cycle is broken due to the rapid onset of action and long acting efficacy against adult fleas on the animal and the absence of viable egg production.
    • Part of treatment strategy for the control of flea allergy dermatitis (FAD) Flea bite hypersensitivity.
    • Contributes to control of the environmental flea populations in areas to which treated cats have access Flea: control.
  • Treatment and control of tick infestations Tick control:
    • Onset of effect is within 48 hours for ticks (I. ricinus Ixodes ricinus, I.scapularis and Dermacentor variabilis).
  • Immediate and persistent tick killing activity for 12 weeks:
    • For 12 weeks:
      • EU: Ixodes ricinus.
      • US: Ixodes scapularis.
    • For 8 weeks:
      • ​US: Dermacentor variabilis (American dog tick).

Efficacy against other ectoparasites

  • Lynxacarus radovskyi  Lynxacarus radovskyi mites were eliminated 4 weeks post treatment in infested cats. 
  • A single topical treatment of cats with fluralaner reduced the mean mite count of Otodectes cynotis Otodectes cynotis by 100% 28 days post treatment.


This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login


This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login


This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login


with other drugs

  • None known.
  • Theoretical competition with other highly bound drugs (eg non-steroidal anti-inflammatory drugs (NSAIDs). However, protein binding of fluralaner, carprofen or warfarin was not reduced in an in vitro study in dog plasma using the maximum expected plasma concentrations.
  • No interactions with routinely used veterinary medicinal products in cats during clinical field trials.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading


Refereed papers

  • Recent references from VetMed Resource and PubMed.
  • Curtis C F, Bourdeau P J, Barr P A, Mukherjee R (2019) Use of the novel ectoparasiticide fluralaner in the treatment of feline sarcoptic mange. Veterinary Record Case Report7, e000772 Abstract.
  • Bosco A, Leone F, Vascone R, Pennacchio S, Ciuca L, Cringoli G, Rinaldi L (2019) Efficacy of fluralaner spot-on solution for the treatment of Ctenocephalides felis and Otodectes cynotis mixed infestation in naturally infested cats. BMC Vet Res 15, 28 PubMed Article.
  • Dryden MW, Canfield MS, Bocon C, Phan L, Niedfeldt E, Kinnon A, Warcholek SA, Smith V, Bress TS, Smith N, Heaney K, Royal C, Normile D, Armstrong R, Sun F (2018) In-home assessment of either topical fluralaner or topical selamectin for flea control in naturally infested cats in West Central Florida, USA. Parasit Vectors 11, 422 PubMed Article.
  • Duangkaew L, Hoffman H (2018) Efficacy of oral fluralaner for the treatment of Demodex gatoi in two shelter cats. Vet Dermatol 29, 262 PubMed.
  • Geurden T, Borowski S, Wozniakiewicz M, King V, Fourie J, Liebenberg J  (2017) Comparative efficacy of a new spot-on combination product containing selamectin and sarolaner (Stronghold®Plus) versus fluralaner (Bravecto®) against induced infestations with Ixodes ricinus ticks on cats. Parasit Vectors 10, 319 PubMed Article.
  • Meadows C, Guerino F, Sun F (2017) A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling feline flea infestations. Parasit Vectors 10, 37 PubMed Article.
  • Taenzler J, de Vos C, Roepke R K A (2016) Efficacy of fluralaner against Otodectes cynotis infestations in dogs and cats. Parasites and Vectors 10, 30 PubMed.
  • Han H S, Noli C & Cena T (2016) Efficacy and duration of action of oral fluralaner and spot-on moxidectin/imidacloprid in cats infested with Lynxacarus radovskyi. Vet Dermatol 27, 474 PubMed.
  • Walther F M, Allan M J, Roepke R K A (2016) Safety of concurrent treatment of cats with fluralaner and emodespsid-praziquantel. Parasites and Vectors 9, 322 PubMed.
  • Kilp S, Ramirez D, Allan M J, Roepke R K (2016) Comparative pharmacokinetics of fluralaner in dogs and cats following single topical or intravenous administration. Parasit Vectors 9, 296  PubMed Article.
  • Asahi M, Kobayashi M, Matsui H, Nakahira K (2014) Differential mechanisms of action of the novel ³-aminobutyric acid receptor antagonist ectoparasiticides fluralaner (A1443) and fipronil. Pest Manag Sci 71 (1), 91-95 PubMed.
  • Gassel M, Wolf C, Noack S, Williams H, Ilg T (2014) The novel isoxazoline ectoparasiticide fluralaner: selective inhibition of arthropod ³-aminobutyric acid- and L-glutamate-gated chloride channels and insecticidal/acaricidal activity. Insect Biochem Mol Biol 45, 111-124 PubMed Article.

Other sources of information